« Combined intoxication with méthylone and 5-MeO-MIPT », Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 31, no 1, , p. 288–91 (PMID16876302, DOI10.1016/j.pnpbp.2006.06.012)
Wagmann L, Richter LH, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR, « In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures », Analytical and Bioanalytical Chemistry, vol. 411, no 19, , p. 4751–4763 (PMID30617391, DOI10.1007/s00216-018-1558-9)
Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, Wallach J, Halberstadt AL, « Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diéthylamide (1B-LSD) », Drug Testing and Analysis, vol. 11, no 8, , p. 1122–1133 (PMID31083768, DOI10.1002/dta.2613)
Brandt SD, Kavanagh PV, Westphal F, Stratford A, Odland AU, Klein AK, Dowling G, Dempster NM, Wallach J, Passie T, Halberstadt AL, « Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diéthylamide (1CP-LSD) », Drug Testing and Analysis, (PMID32180350, DOI10.1002/dta.2789)
(ja) Uchiyama N, Miyazawa N, Kawamura M, Kikura-Hanajiri R, Goda Y, « [Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008] », Yakugaku Zasshi, vol. 130, no 2, , p. 263–70 (PMID20118651, DOI10.1248/yakushi.130.263)
Richard A. Glennon, Mikhail L. Bondarev, Nantaka Khorana, Richard Young, Jesse A. May, Mark R. Hellberg, Marsha A. McLaughlin et Najam A. Sharif, « β-Oxygenated Analogues of the 5-HT2ASerotonin Receptor Agonist 1-(4-Bromo-2,5-diméthoxyphenyl)-2-aminopropane », Journal of Medicinal Chemistry, vol. 47, no 24, , p. 6034–6041 (ISSN0022-2623, PMID15537358, DOI10.1021/jm040082s)
Kaizaki-Mitsumoto A, Noguchi N, Yamaguchi S, Odanaka Y, Matsubayashi S, Kumamoto H, Fukuhara K, Funada M, Wada K, Numazawa S, « Three 25-NBOMe-type drugs, three other phenéthylamine-type drugs (25I-NBMD, RH34, and escaline), eight cathinone derivatives, and a phencyclidine analog MMXE, newly identified in ingredients of drug products before they were sold on the drug market », Forensic Toxicology, vol. 34, no 1, , p. 108–114 (ISSN1860-8965, DOI10.1007/s11419-015-0293-6)
Morris H, Wallach J, « From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs », Drug Testing and Analysis, vol. 6, nos 7-8, , p. 614–32 (PMID24678061, DOI10.1002/dta.1620)
Uchiyama N, Shimokawa Y, Kikura-Hanajiri R, Demizu Y, Goda Y, Hakamatsuka T, « N-OH-EDMA, and a cathinone derivative diméthoxy-α-PHP, newly identified in illegal products », Forensic Toxicology, vol. 33, no 2, , p. 244–259 (PMID26257833, PMCID4525202, DOI10.1007/s11419-015-0268-7)
Uchiyama N, Matsuda S, Kawamura M, Shimokawa Y, Kikura-Hanajiri R, Aritake K, Urade Y, Goda Y, « Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products », Forensic Science International, vol. 243, , p. 1–13 (PMID24769262, DOI10.1016/j.forsciint.2014.03.013)
Weiß JA, Taschwer M, Kunert O, Schmid MG, « Analysis of a new drug of abuse: cathinone derivative 1-(3,4-diméthoxyphenyl)-2-(éthylamino)pentan-1-one », Journal of Separation Science, vol. 38, no 5, , p. 825–8 (PMID25545103, DOI10.1002/jssc.201401052)
Gaspar H, Bronze S, Ciríaco S, Queirós CR, Matias A, Rodrigues J, Oliveira C, Cordeiro C, Santos S, « 4F-PBP (4'-fluoro-α-pyrrolidinobutyrophenone), a new substance of abuse: Structural characterization and purity NMR profiling », Forensic Science International, vol. 252, , p. 168–76 (PMID26005857, DOI10.1016/j.forsciint.2015.05.003)
Shintani-Ishida K, Nakamura M, Tojo M, Idota N, Ikegaya H, « Identification and quantification of 4′-méthoxy-α-pyrrolidinobutiophenone (4-MeOPBP) in human plasma and urine using LC–TOF-MS in an autopsy case », Forensic Toxicology, vol. 33, no 2, , p. 348–354 (DOI10.1007/s11419-015-0281-x)
McLaughlin G, Baumann MH, Kavanagh PV, Morris N, Power JD, Dowling G, Twamley B, O'Brien J, Hessman G, Westphal F, Walther D, Brandt SD, « Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-méthylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers », Drug Testing and Analysis, vol. 10, no 9, , p. 1404–1416 (PMID29673128, DOI10.1002/dta.2396, lire en ligne)
Power JD, Scott KR, Gardner EA, Curran McAteer BM, O'Brien JE, Brehon M, Talbot B, Kavanagh PV, « The syntheses, characterization and in vitro metabolism of nitracaine, méthoxypiperamide and mephtetramine », Drug Testing and Analysis, vol. 6, nos 7-8, , p. 668–75 (PMID24574100, DOI10.1002/dta.1616)
Oldenhof S, Ten Pierick A, Bruinsma J, Eustace S, Hulshof J, van den Berg J, Hoitink M, « Identification of a novel fentanyl analog: p-Hydroxy-butyrylfentanyl », Drug Testing and Analysis, vol. 12, no 1, , p. 152–155 (PMID31518047, DOI10.1002/dta.2695)
Kennedy NM, Schmid CL, Ross NC, Lovell KM, Yue Z, Chen YT, Cameron MD, Bohn LM, Bannister TD, « Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias », Journal of Medicinal Chemistry, vol. 61, no 19, , p. 8895–8907 (PMID30199635, PMCID6386185, DOI10.1021/acs.jmedchem.8b01136)
Krotulski AJ, Mohr AL, Papsun DM, Logan BK, « Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug users », Drug Testing and Analysis, vol. 10, no 1, , p. 127–136 (PMID28608586, DOI10.1002/dta.2228)
Huppertz LM, Bisel P, Westphal F, Franz F, Auwärter V, Moosmann B, « Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites », Forensic Toxicology, vol. 33, no 2, , p. 388–395 (DOI10.1007/s11419-015-0277-6)
Lukas Mogler, Florian Franz, Maurice Wilde, Laura M. Huppertz, Sebastian Halter, Verena Angerer, Bjoern Moosmann et Volker Auwärter, « Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples », Drug Testing and Analysis, vol. 10, no 9, , p. 1417–1429 (ISSN1942-7611, PMID29726116, DOI10.1002/dta.2398)
Qian Z, Jia W, Li T, Hua Z, Liu C, « Identification and analytical characterization of four synthetic cannabinoids ADB-BICA, NNL-1, NNL-2, and PPA(N)-2201 », Drug Testing and Analysis, vol. 9, no 1, , p. 51–60 (PMID27239006, DOI10.1002/dta.1990)
Krotulski AJ, Mohr AL, Kacinko SL, Fogarty MF, Shuda SA, Diamond FX, Kinney WA, Menendez MJ, Logan BK, « 4F-MDMB-BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework », Journal of Forensic Sciences, vol. 64, no 5, , p. 1451–1461 (PMID31260580, DOI10.1111/1556-4029.14101)
Haschimi B, Mogler L, Halter S, Giorgetti A, Schwarze B, Westphal F, Fischmann S, Auwärter V, « Detection of the recently emerged synthetic cannabinoid 4F-MDMB-BINACA in "legal high" products and human urine specimens », Drug Testing and Analysis, vol. 11, no 9, , p. 1377–1386 (PMID31228224, DOI10.1002/dta.2666)
Qian Z, Hua Z, Liu C, Jia W, « Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances », Forensic Toxicology, vol. 34, no 1, , p. 133–143 (PMID26793280, PMCID4705129, DOI10.1007/s11419-015-0297-2)
Krotulski AJ, Mohr AL, Diamond FX, Logan BK, « Detection and characterization of the new synthetic cannabinoid APP-BINACA in forensic casework », Drug Testing and Analysis, vol. 12, no 1, , p. 136–144 (PMID31788963, DOI10.1002/dta.2698)
Nakajima JI, Takahashi M, Uemura N, Seto T, Fukaya H, Suzuki J, Yoshida M, Kusano M, Nakayama H, Zaitsu K, Ishii A, « Identification of N,N-bis(1-pentylindol-3-yl-carboxy)naphthylamine (BiPICANA) found in an herbal blend product in the Tokyo metropolitan area and its cannabimimetic effects evaluated by in vitro [35S]GTPγS binding assays », Forensic Toxicology, vol. 33, , p. 84–92 (DOI10.1007/s11419-014-0253-6)
Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M, « Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA », ACS Chemical Neuroscience, vol. 6, no 9, , p. 1546–59 (PMID26134475, DOI10.1021/acschemneuro.5b00112)
Mogler L, Wilde M, Huppertz LM, Weinfurtner G, Franz F, Auwärter V, « Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples », Drug Testing and Analysis, vol. 10, no 5, , p. 886–891 (PMID29314750, DOI10.1002/dta.2352)
Wiley JL, Lefever TW, Cortes RA, Marusich JA, « Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats », Pharmacology, Biochemistry, and Behavior, vol. 124, , p. 123–8 (PMID24887450, PMCID4150816, DOI10.1016/j.pbb.2014.05.016)
« Advances in the detection of designer steroids in anti-doping », Bioanalysis, vol. 6, no 6, , p. 881–96 (PMID24702116, DOI10.4155/bio.14.9)
« Deciphering the selective androgen receptor modulators paradigm », Expert Opinion on Drug Discovery, vol. 8, no 2, , p. 191–218 (PMID23231475, DOI10.1517/17460441.2013.741582)
Zhang X, Li X, Allan GF, Sbriscia T, Linton O, Lundeen SG, Sui Z, « Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators », Bioorganic & Medicinal Chemistry Letters, vol. 17, no 2, , p. 439–43 (PMID17079140, DOI10.1016/j.bmcl.2006.10.035)
Allan GF, Tannenbaum P, Sbriscia T, Linton O, Lai MT, Haynes-Johnson D, Bhattacharjee S, Zhang X, Sui Z, Lundeen SG, « A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats », Endocrine, vol. 32, no 1, , p. 41–51 (PMID17992601, DOI10.1007/s12020-007-9005-2)
Kanno Y, Ota R, Someya K, Kusakabe T, Kato K, Inouye Y, « Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression », Biological & Pharmaceutical Bulletin, vol. 36, no 9, , p. 1460–5 (PMID23995658, DOI10.1248/bpb.b13-00231)
« Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition », Journal of Medicinal Chemistry, vol. 58, no 3, , p. 1544–9 (PMID25569186, DOI10.1021/jm501170d)
Richard A. Glennon, Mikhail L. Bondarev, Nantaka Khorana, Richard Young, Jesse A. May, Mark R. Hellberg, Marsha A. McLaughlin et Najam A. Sharif, « β-Oxygenated Analogues of the 5-HT2ASerotonin Receptor Agonist 1-(4-Bromo-2,5-diméthoxyphenyl)-2-aminopropane », Journal of Medicinal Chemistry, vol. 47, no 24, , p. 6034–6041 (ISSN0022-2623, PMID15537358, DOI10.1021/jm040082s)
Kaizaki-Mitsumoto A, Noguchi N, Yamaguchi S, Odanaka Y, Matsubayashi S, Kumamoto H, Fukuhara K, Funada M, Wada K, Numazawa S, « Three 25-NBOMe-type drugs, three other phenéthylamine-type drugs (25I-NBMD, RH34, and escaline), eight cathinone derivatives, and a phencyclidine analog MMXE, newly identified in ingredients of drug products before they were sold on the drug market », Forensic Toxicology, vol. 34, no 1, , p. 108–114 (ISSN1860-8965, DOI10.1007/s11419-015-0293-6)
Lukas Mogler, Florian Franz, Maurice Wilde, Laura M. Huppertz, Sebastian Halter, Verena Angerer, Bjoern Moosmann et Volker Auwärter, « Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples », Drug Testing and Analysis, vol. 10, no 9, , p. 1417–1429 (ISSN1942-7611, PMID29726116, DOI10.1002/dta.2398)
ljmu.ac.uk
researchonline.ljmu.ac.uk
McLaughlin G, Baumann MH, Kavanagh PV, Morris N, Power JD, Dowling G, Twamley B, O'Brien J, Hessman G, Westphal F, Walther D, Brandt SD, « Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-méthylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers », Drug Testing and Analysis, vol. 10, no 9, , p. 1404–1416 (PMID29673128, DOI10.1002/dta.2396, lire en ligne)
nih.gov
ncbi.nlm.nih.gov
« Combined intoxication with méthylone and 5-MeO-MIPT », Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 31, no 1, , p. 288–91 (PMID16876302, DOI10.1016/j.pnpbp.2006.06.012)
Wagmann L, Richter LH, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR, « In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures », Analytical and Bioanalytical Chemistry, vol. 411, no 19, , p. 4751–4763 (PMID30617391, DOI10.1007/s00216-018-1558-9)
Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, Wallach J, Halberstadt AL, « Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diéthylamide (1B-LSD) », Drug Testing and Analysis, vol. 11, no 8, , p. 1122–1133 (PMID31083768, DOI10.1002/dta.2613)
Brandt SD, Kavanagh PV, Westphal F, Stratford A, Odland AU, Klein AK, Dowling G, Dempster NM, Wallach J, Passie T, Halberstadt AL, « Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diéthylamide (1CP-LSD) », Drug Testing and Analysis, (PMID32180350, DOI10.1002/dta.2789)
(ja) Uchiyama N, Miyazawa N, Kawamura M, Kikura-Hanajiri R, Goda Y, « [Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008] », Yakugaku Zasshi, vol. 130, no 2, , p. 263–70 (PMID20118651, DOI10.1248/yakushi.130.263)
Richard A. Glennon, Mikhail L. Bondarev, Nantaka Khorana, Richard Young, Jesse A. May, Mark R. Hellberg, Marsha A. McLaughlin et Najam A. Sharif, « β-Oxygenated Analogues of the 5-HT2ASerotonin Receptor Agonist 1-(4-Bromo-2,5-diméthoxyphenyl)-2-aminopropane », Journal of Medicinal Chemistry, vol. 47, no 24, , p. 6034–6041 (ISSN0022-2623, PMID15537358, DOI10.1021/jm040082s)
Morris H, Wallach J, « From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs », Drug Testing and Analysis, vol. 6, nos 7-8, , p. 614–32 (PMID24678061, DOI10.1002/dta.1620)
Uchiyama N, Shimokawa Y, Kikura-Hanajiri R, Demizu Y, Goda Y, Hakamatsuka T, « N-OH-EDMA, and a cathinone derivative diméthoxy-α-PHP, newly identified in illegal products », Forensic Toxicology, vol. 33, no 2, , p. 244–259 (PMID26257833, PMCID4525202, DOI10.1007/s11419-015-0268-7)
Uchiyama N, Matsuda S, Kawamura M, Shimokawa Y, Kikura-Hanajiri R, Aritake K, Urade Y, Goda Y, « Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products », Forensic Science International, vol. 243, , p. 1–13 (PMID24769262, DOI10.1016/j.forsciint.2014.03.013)
Weiß JA, Taschwer M, Kunert O, Schmid MG, « Analysis of a new drug of abuse: cathinone derivative 1-(3,4-diméthoxyphenyl)-2-(éthylamino)pentan-1-one », Journal of Separation Science, vol. 38, no 5, , p. 825–8 (PMID25545103, DOI10.1002/jssc.201401052)
Gaspar H, Bronze S, Ciríaco S, Queirós CR, Matias A, Rodrigues J, Oliveira C, Cordeiro C, Santos S, « 4F-PBP (4'-fluoro-α-pyrrolidinobutyrophenone), a new substance of abuse: Structural characterization and purity NMR profiling », Forensic Science International, vol. 252, , p. 168–76 (PMID26005857, DOI10.1016/j.forsciint.2015.05.003)
McLaughlin G, Baumann MH, Kavanagh PV, Morris N, Power JD, Dowling G, Twamley B, O'Brien J, Hessman G, Westphal F, Walther D, Brandt SD, « Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-méthylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers », Drug Testing and Analysis, vol. 10, no 9, , p. 1404–1416 (PMID29673128, DOI10.1002/dta.2396, lire en ligne)
Power JD, Scott KR, Gardner EA, Curran McAteer BM, O'Brien JE, Brehon M, Talbot B, Kavanagh PV, « The syntheses, characterization and in vitro metabolism of nitracaine, méthoxypiperamide and mephtetramine », Drug Testing and Analysis, vol. 6, nos 7-8, , p. 668–75 (PMID24574100, DOI10.1002/dta.1616)
Oldenhof S, Ten Pierick A, Bruinsma J, Eustace S, Hulshof J, van den Berg J, Hoitink M, « Identification of a novel fentanyl analog: p-Hydroxy-butyrylfentanyl », Drug Testing and Analysis, vol. 12, no 1, , p. 152–155 (PMID31518047, DOI10.1002/dta.2695)
Kennedy NM, Schmid CL, Ross NC, Lovell KM, Yue Z, Chen YT, Cameron MD, Bohn LM, Bannister TD, « Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias », Journal of Medicinal Chemistry, vol. 61, no 19, , p. 8895–8907 (PMID30199635, PMCID6386185, DOI10.1021/acs.jmedchem.8b01136)
Krotulski AJ, Mohr AL, Papsun DM, Logan BK, « Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug users », Drug Testing and Analysis, vol. 10, no 1, , p. 127–136 (PMID28608586, DOI10.1002/dta.2228)
Lukas Mogler, Florian Franz, Maurice Wilde, Laura M. Huppertz, Sebastian Halter, Verena Angerer, Bjoern Moosmann et Volker Auwärter, « Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples », Drug Testing and Analysis, vol. 10, no 9, , p. 1417–1429 (ISSN1942-7611, PMID29726116, DOI10.1002/dta.2398)
Qian Z, Jia W, Li T, Hua Z, Liu C, « Identification and analytical characterization of four synthetic cannabinoids ADB-BICA, NNL-1, NNL-2, and PPA(N)-2201 », Drug Testing and Analysis, vol. 9, no 1, , p. 51–60 (PMID27239006, DOI10.1002/dta.1990)
Krotulski AJ, Mohr AL, Kacinko SL, Fogarty MF, Shuda SA, Diamond FX, Kinney WA, Menendez MJ, Logan BK, « 4F-MDMB-BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework », Journal of Forensic Sciences, vol. 64, no 5, , p. 1451–1461 (PMID31260580, DOI10.1111/1556-4029.14101)
Haschimi B, Mogler L, Halter S, Giorgetti A, Schwarze B, Westphal F, Fischmann S, Auwärter V, « Detection of the recently emerged synthetic cannabinoid 4F-MDMB-BINACA in "legal high" products and human urine specimens », Drug Testing and Analysis, vol. 11, no 9, , p. 1377–1386 (PMID31228224, DOI10.1002/dta.2666)
Qian Z, Hua Z, Liu C, Jia W, « Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances », Forensic Toxicology, vol. 34, no 1, , p. 133–143 (PMID26793280, PMCID4705129, DOI10.1007/s11419-015-0297-2)
Krotulski AJ, Mohr AL, Diamond FX, Logan BK, « Detection and characterization of the new synthetic cannabinoid APP-BINACA in forensic casework », Drug Testing and Analysis, vol. 12, no 1, , p. 136–144 (PMID31788963, DOI10.1002/dta.2698)
Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M, « Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA », ACS Chemical Neuroscience, vol. 6, no 9, , p. 1546–59 (PMID26134475, DOI10.1021/acschemneuro.5b00112)
Mogler L, Wilde M, Huppertz LM, Weinfurtner G, Franz F, Auwärter V, « Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples », Drug Testing and Analysis, vol. 10, no 5, , p. 886–891 (PMID29314750, DOI10.1002/dta.2352)
Wiley JL, Lefever TW, Cortes RA, Marusich JA, « Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats », Pharmacology, Biochemistry, and Behavior, vol. 124, , p. 123–8 (PMID24887450, PMCID4150816, DOI10.1016/j.pbb.2014.05.016)
« Advances in the detection of designer steroids in anti-doping », Bioanalysis, vol. 6, no 6, , p. 881–96 (PMID24702116, DOI10.4155/bio.14.9)
« Deciphering the selective androgen receptor modulators paradigm », Expert Opinion on Drug Discovery, vol. 8, no 2, , p. 191–218 (PMID23231475, DOI10.1517/17460441.2013.741582)
Zhang X, Li X, Allan GF, Sbriscia T, Linton O, Lundeen SG, Sui Z, « Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators », Bioorganic & Medicinal Chemistry Letters, vol. 17, no 2, , p. 439–43 (PMID17079140, DOI10.1016/j.bmcl.2006.10.035)
Allan GF, Tannenbaum P, Sbriscia T, Linton O, Lai MT, Haynes-Johnson D, Bhattacharjee S, Zhang X, Sui Z, Lundeen SG, « A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats », Endocrine, vol. 32, no 1, , p. 41–51 (PMID17992601, DOI10.1007/s12020-007-9005-2)
Kanno Y, Ota R, Someya K, Kusakabe T, Kato K, Inouye Y, « Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression », Biological & Pharmaceutical Bulletin, vol. 36, no 9, , p. 1460–5 (PMID23995658, DOI10.1248/bpb.b13-00231)
« Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition », Journal of Medicinal Chemistry, vol. 58, no 3, , p. 1544–9 (PMID25569186, DOI10.1021/jm501170d)
